LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT07361679

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Alexandra Hospital, Athens, Greece (from the registry)
Registry
  • NCT NCT07361679
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Greece (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07361679. Randomized; no masking; primary purpose prevention. Start 2023-01-18 (actual); primary completion 2026-11-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention
Acronym
preGO
Condition
Preeclampsia Severe
Condition
Toxemia Of Pregnancy
Condition
Preeclampsia
Condition
Pregnancy Complications
Condition
Hypertension, Pregnancy-Induced
Condition
Gestational Hypertension
Intervention (Drug)
Aspirin
Intervention (Drug)
Tinzaparin
Lead sponsor
Alexandra Hospital, Athens, Greece (class: other)

Record details

Record id
cardio:ct-nct07361679
Content hash
aab98891a95ea0967714e197154b564a613ef135fccd9e47f82792feb446aa52